Tag Archive for: Novavax

The company announced plans to cut 25% of its workforce and unveiled promising data for its COVID-influenza combination vaccine and two other shots, raising hopes of a recovery for the cash-strapped biotech.

At the World Vaccine Congress in Washington, D.C. on Wednesday, Maryland-based Novavax presented data on its COVID-19 booster and COVID-influenza combination vaccine candidate. Novavax shares rose 12 percent Thursday following the presentation. 

On February 28, Novavax issued a candid warning to investors: it may not be able to continue operations beyond February 2024.

Novavax Inc.’s shares plunged 28% in U.S. early trading on Wednesday, a day after the COVID-19 vaccine maker raised doubts about its ability to remain in business.

The U.S. government has agreed to buy 1.5 million more doses of Novavax Inc. COVID-19 vaccine, the company said on Monday, adding that the modified agreement includes funds for development of an updated vaccine by fall this year.

France’s Haute Autorite de Sante public health body advised the government not to use Valneva’s VLA2001 COVID-19 vaccine as part of its wider vaccination strategy, although two rival products should be included as booster shots.

The company cited Gavi’s failure to procure the 350 million doses it had agreed to buy in May last year for the COVAX facility.

Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.

Pfizer Inc. on Tuesday raised its forecast for annual sales of its COVID-19 vaccine by $2 billion to $34 billion on demand for Omicron-targeted boosters, helping allay some investor worries over growth for the vaccinations.

With most Americans delaying or skipping new COVID-19 booster shots, analysts and investors are now predicting far fewer will be given each year, pushing the number of shots well below annual flu vaccinations.